Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Glycoform Elimination in Healthy Subjects
NCT02570373Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoint: Change in Rate of Elimination of Guselkumab Glycoform Variants up to 43 days. Started Sep 2015; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02570373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570373.